BullFrog AI Holdings, Inc. Business Update and Financial Position

BullFrog AI Holdings, Inc. has issued a business update and a letter to its shareholders. The company has secured its first commercial agreement with a top 5 global pharmaceutical company for its bfLEAP® platform to identify drug targets for major depressive disorder. This agreement, along with others, validates the company's AI-driven drug discovery approach. BullFrog AI has also strengthened its balance sheet, securing a financial runway into late 2027 and complying with Nasdaq's minimum stockholders' equity listing standard. The company is focused on deepening relationships with existing partners, advancing discussions with other organizations, and expanding the adoption of its AI platform. BullFrog AI emphasizes its unique, integrated AI platform for pharmaceutical R&D, from data preparation to strategic decision-making.